ARTICLE | Clinical News
Humira adalimumab: Marketed
November 3, 2003 8:00 AM UTC
Updated data from 3 double-blind Phase III trials showed Humira 40 mg every other week plus methotrexate significantly decreased the mean HAQ Disability Index in each trial at 24 weeks compared to pla...